Table 1. Ten most-represented pneumococcal serotypes in the British Society for Antimicrobial Chemotherapy bacteraemia surveillance, United Kingdom and Republic of Ireland, 2001–2014 (n = 3,206 isolates).
| Serotype (bold); number and proportion of isolates | % for top 10a | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rank | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ||||||||||||||||||||
| 2001 (n = 227) |
14 | 8 | 9V | 23F | 3 | 4 | 6B | 12F | NA | NA | 1 | 9F | NA | 71.4% | ||||||||||||||||
| n = 36 15.9% |
n = 23 10.1% |
n = 20 8.8% |
n = 17 7.5% |
n = 15 6.6% |
n = 11 4.8% |
NA | NA | n = 9 4.0% |
NA | |||||||||||||||||||||
| 2002 (n = 220) |
14 | 9V | 6B | 19F | 23F | NA | NA | 1 | 22F | 8 | 3 | 4 | 7F | 6A | 69.5% | |||||||||||||||
| 19A | 20 | |||||||||||||||||||||||||||||
| n = 42 19.1% |
n = 24 10.9% |
n = 14 6.4% |
NA | NA | n = 11 5.0% |
n = 10 4.5% |
n = 9 4.1% |
n = 8 3.6% |
n = 7 3.2% |
|||||||||||||||||||||
| 2003 (n = 239) |
14 | 9V | 1 | 4 | 8 | 23F | 3 | 19F | NA | 6B | 18C | 72.0% | ||||||||||||||||||
| n = 34 14.2% |
n = 30 12.6% |
n = 21 8.8% |
n = 17 7.1% |
n = 16 6.7% |
n = 13 5.4% |
n = 11 4.6% |
NA | n = 10 4.2% |
n = 6 3.8% |
|||||||||||||||||||||
| 2004 (n = 241) |
14 | 1 | 19F | 4 | 23F | NA | 9V | 8 | 3 | 7F | 19A | 22F | NA | 67.2% | ||||||||||||||||
| n = 37 15.4% |
n = 24 10.0% |
n = 16 6.6% |
n = 14 5.8% |
NA | n = 13 5.4% |
n = 13 5.4% |
n = 11 4.6% |
n = 10 4.1% |
NA | |||||||||||||||||||||
| 2005 (n = 230) |
14 | 1 | 9V | 23F | 3 | 4 | 8 | NA | NA | 19F | 7F | 6B | 75.2% | |||||||||||||||||
| n = 35 15.2% |
n = 30 13.0% |
n = 21 9.1% |
n = 18 7.8% |
n = 14 6.1% |
NA | NA | n = 10 4.3% |
n = 9 3.9% |
n = 8 3.5% |
|||||||||||||||||||||
| 2006 (n = 231) |
1 | 14 | 9V | 23F | 6A | 4 | 6B | 7F | NA | NA | 8 | 18C | NA | 75.8% | ||||||||||||||||
| n = 36 15.6% |
n = 29 12.6% |
n = 22 9.5% |
n = 16 6.9% |
n = 15 6.5% |
n = 13 5.6% |
NA | NA | n = 9 3.9% |
NA | |||||||||||||||||||||
| 2007 (n = 216) |
14 | 1 | 9V | 8 | 7F | 23F | 3 | 4 | 6A | NA | NA | 12F | 77.3% | |||||||||||||||||
| n = 30 13.9% |
n = 26 12.0% |
n = 20 9.3% |
n = 19 8.8% |
n = 14 6.5% |
13 6.0% |
n = 12 5.6% |
NA | NA | n = 9 4.2% |
|||||||||||||||||||||
| 2008 (n = 201) |
1 | 14 | 8 | 7F | 22F | NA | 9V | 19A | 3 | 20 | 4 | 23F | 73.6% | |||||||||||||||||
| n = 32 15.9% |
n = 20 10.0% |
n = 17 8.5% |
n = 15 7.5% |
NA | n = 14 7.0% |
n = 13 6.5% |
n = 9 4.5% |
n = 7 3.5% |
n = 6 3.0% = |
|||||||||||||||||||||
| 2009 (n = 211) |
7F | 3 | 19A | 8 | 22F | 1 | 6A | 14 | 12F | 4 | 71.6% | |||||||||||||||||||
| n = 26 12.3% |
n = 23 10.9% |
n = 18 8.5% |
n = 17 8.1% |
n = 14 6.6% |
n = 13 6.2% |
n = 12 5.7% |
n = 11 5.2% |
n = 9 4.3% |
n = 8 3.8% |
|||||||||||||||||||||
| 2010 (n = 249) |
19A | 7F | 1 | 8 | 33F | 22F | 14 | 3 | 6A | 11A | NA | 68.7% | ||||||||||||||||||
| n = 38 15.3% |
n = 33 13.3% |
n = 21 8.4% |
n = 19 7.6% |
n = 14 5.6% |
n = 11 4.4% |
n = 10 4.0% |
n = 9 3.6% |
n = 8 3.2% |
NA | |||||||||||||||||||||
| 2011 (n = 230) |
7F | 19A | 8 | 3 | 22F | 1 | 23B | 9N | 15A | NA | 12F | 19F | 70.4% | |||||||||||||||||
| n = 29 12.6% |
n = 28 12.2% |
n = 22 9.6% |
n = 19 8.3% |
n = 18 7.8% |
n = 14 6.1% |
n = 9 3.9% |
n = 8 3.5% |
NA | n = 7 3.0% |
|||||||||||||||||||||
| 2012 (n = 229) |
7F | 8 | 22F | 19A | 33F | 12F | 1 | 3 | NA | 6C | 15A | 69.4% | ||||||||||||||||||
| n = 29 12.7% |
n = 27 11.8% |
n = 25 10.9% |
n = 20 8.7% |
n = 12 5.2% |
n = 11 4.8% |
n = 10 4.4% |
NA | n = 8 3.5% |
n = 7 3.1% |
|||||||||||||||||||||
| 2013 (n = 235) |
7F | 8 | NA | 22F | 3 | 19A | NA | 23A | 12F | 15A | 33F | NA | 1 | 11A | 24F | 66.8% | ||||||||||||||
| n = 36 15.3% |
NA | n = 15 6.4% |
n = 14 6.0% |
NA | n = 10 4.3% |
n = 9 3.8% |
n = 8 3.4% |
NA | n = 7 3.0% |
|||||||||||||||||||||
| 2014 (n = 247) |
8 | 22F | 12F | 15A | 19A | 3 | 7F | 9N | 24F | NA | 10A | 71.7% | ||||||||||||||||||
| n = 43 17.4% |
n = 22 8.9% |
n = 20 8.1% |
n = 19 7.7% |
n = 16 6.5% |
n = 14 5.7% |
n = 13 5.3% |
n = 11 4.5% |
NA | n = 8 3.2% |
|||||||||||||||||||||
NA: not applicable.
Green: covered by PCV7; yellow: additional types covered by PCV13; pink: not covered by any conjugate vaccine.
a When there is a tie for tenth rank, only one of the tied serotypes is counted into the percentage total for the top 10.